Search Within

Gunjan Lalitchandra Shah

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (60)
  2. Journal Article (17)
  3. Research Letter (7)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (85)
  2. Center for Hematologic Malignancies (85)
  3. Department of Medicine (85)
  4. Hematologic Malignancies, Division of (85)
  5. Population Sciences Research Program (85)
  6. Survivorship Research (85)

More Groups

People
  1. Sergio Giralt (73)
  2. Michael Scordo (67)
  3. Sham Mailankody (57)
  4. Alexander Lesokhin (54)
  5. Hani Hassoun (54)
  6. Malin Hultcrantz (54)

More People

Years
  1. 2025 (3)
  2. 2024 (11)
  3. 2023 (22)
  4. 2022 (18)
  5. 2021 (11)
  6. 2020 (9)

More Years

Publications
  1. Blood (34)
  2. Clinical Lymphoma, Myeloma and Leukemia (15)
  3. Journal of Clinical Oncology (8)
  4. Leukemia and Lymphoma (4)
  5. American Journal of Hematology (3)
  6. Biology of Blood and Marrow Transplantation (3)

More Publications

Publishers
  1. American Society of Hematology (36)
  2. Elsevier Inc. (20)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (6)
  5. Taylor & Francis Group (4)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (85)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Research Letter

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation
    Research Letter

    Lin, R. J.; Baser, R. E.; Elko, T. A.; Korc-Grodzicki, B.; Shahrokni, A.; Maloy, M. A.; Young, J. W.; Tamari, R.; Shah, G. L.; Shaffer, B. C.; more...
    Bone Marrow Transplantation (2021)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save